Impact of Oral Magnesium on Neuropathic Pain

University Hospital, Clermont-Ferrand

Status and phase: Completed; Phase 4

Conditions: Patient With Neuropathic Pain

Treatments: Drug: Magnogene ® (magnesium)

Study type: Interventional

Funder types: Other

Identifiers

NCT01121653

CHU-0073

Details and patient eligibility

About

Use lay language.

The aim of this study is to evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.

Full description

Protocol description

Visit D0

• patient inclusion after informed signed consent
• clinical exam
• blood sampling (magnesium dosage)
• questionnaires (neuropathic pain and quality of life)
• daily self-evaluation on neuropathic pain scale (Week0 to Week5)

D8 : first intake of study drug (magnesium or placebo)

Visit Week5:

• questionnaires (neuropathic pain and quality of life)
• blood sampling (magnesium dosage)
• clinical exam

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• neuropathic pain

• informed signed consent

Exclusion criteria

• magnesium intake contra-indication
• severe renal insufficiency
• quinidine intake
• concomitant treatment change 2weeks before inclusion
• evolutive pathology